SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare informs about company updates

25 Oct 2019 Evaluate

Shilpa Medicare has informed that the Company has received US FDA Establishment Inspection Report (EIR) on 24 October 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla, Telangana State, India. The company’s finished dosage form facility was inspected by US FDA from 29th August to 6th September, 2019. FDA has concluded the inspection, with determination that the inspection classification of this facility is ‘voluntary action indicated’ (VAI). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP). 

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×